Imatinib Inteli

Imatinib, the active ingredient in Imatinib Inteli, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Inteli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib is a targeted tyrosine‑kinase inhibitor used in several hematologic and solid‑tumor malignancies. - Chronic myeloid leukemia (CML): suppresses BCR‑ABL driven proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): adds to remission rates when combined with chemotherapy. - Gastrointestinal stromal tumor (GIST): blocks c‑KIT signaling to reduce tumor growth.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Muscle cramps: intermittent skeletal muscle discomfort. - Fatigue: generalized lack of energy. - Diarrhea: loose stools, sometimes watery. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Neutropenia: significant drop in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced left‑ventricular function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: increased pressure in lung arteries. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor appropriately. - Renal or hepatic impairment: adjust monitoring and consider dose modification. - Cardiac disease: assess baseline function and watch for signs of heart failure. - Concomitant CYP3A4 inhibitors: avoid dose escalation without supervision. - Pregnancy: avoid use unless benefits outweigh potential fetal risk. - Bleeding risk: monitor coagulation parameters in patients on anticoagulants. - Store at ambient temperature: keep in original container, protect from moisture and light.

Imatinib may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic exposure. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may lower oral absorption. - QT‑prolonging agents: monitor ECG for arrhythmia risk. - Live vaccines: reduced immunogenicity, consider timing of administration.